A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Inclusion Criteria: * Ages 20 years and over. * Unresectable pancreatic cancer (including metastatic pancreatic cancer) who are refractory or intolerant to first-line chemotherapy. Any first-line chemotherapy is acceptable. * Target treatment tumor is located in the pancreas, and the target tumor can be visualized with ultrasound echography and can also be treated by high-intensity focused ultrasound. * Has primary tumor site of measurable lesion according to RECIST guidelines version 1.1 * ECOG performance status of 0 to 2. Exclusion Criteria: * Active multiple cancers that require treatment. * Suspected gastrointestinal invasion of the primary tumor based on CT scan. * Obstructive jaundice. However, patients who have a bile duct stent placed for obstructive jaundice by the time of allocation may be enrolled. * Child-Pugh Classification B or C liver failure due to liver metastases. * Tumor embolization in the veins surrounding the pancreas. * Cystic component within the pancreatic cancer. * Peritoneal dissemination. * Pleural effusion or ascites with poorly controlled * Contraindications to the use of secondary chemotherapy used in this study.